Lazertinib Successfully Establishes Itself in the European Market

Yuhan Corporation’s non-small cell lung cancer treatment, ‘Lazertinib’ (ingredient name: lazertinib), has successfully entered the European market. Last May, Yuhan Corporation received a $30 million milestone payment as the European commercialization of the combination therapy of Lazertinib and Amivantamab, which was previously licensed to Janssen Biotech, commenced. With this European commercialization, Lazertinib’s cumulative milestones, including the upfront payment, have reached a total of $300 million. Having entered four continents – Asia, Europe, America, and Oceania – Lazertinib is establishing itself as a truly global new drug, and future sales royalty revenues are also anticipated. This is clear evidence that Yuhan Corporation has secured strong competitiveness in the global pharmaceutical market based on its technological prowess.

Securing Future Growth Engines with CDMO Business Expansion

In addition to Lazertinib, Yuhan Corporation is securing new growth engines through its active pharmaceutical ingredient (API) (CDMO) business. Led by its subsidiary Yuhan Chemical, the overseas business sector continues to show steady growth, and the expansion of global supply contracts, particularly for human immunodeficiency virus (HIV) treatments, positions the CDMO business as a mid-to-long-term growth engine for Yuhan Corporation. Yuhan Chemical boasts a total annual production capacity of 995,000 liters through its Ansan and Hwaseong plants and is pursuing additional expansion targeting operation in 2028 to meet increasing production demands. With the strengthening of global biosecurity laws leading to increased demand for diversification of API supply chains, Yuhan Corporation’s CDMO business is clearly set for further success.

100th Anniversary, the Status of ‘Most Respected Company’

2026 is a very meaningful year for Yuhan Corporation, marking its 100th anniversary. Founded in 1926 based on the belief of its founder, the late Dr. Yu Il-han, that ‘only healthy citizens can reclaim lost sovereignty,’ Yuhan Corporation has safeguarded public health security in South Korea for the past century. This founding spirit continues to this day, achieving the remarkable feat of being ranked 1st in the pharmaceutical sector for 23 consecutive years and 4th overall in the All-Star category in the ‘2026 Korea’s Most Respected Companies’ survey published by the Korea Management Association. This demonstrates that Yuhan Corporation’s transparent management and commitment to social responsibility are highly regarded externally. It can be seen as a prime example of a ‘good life’ company that contributes to creating social value beyond merely pursuing profits.

Yuhan Corporation is presenting an even more solid vision with the global commercialization success of Lazertinib, the expansion of its CDMO business, and its 100th anniversary. The goal of contributing to the health and happiness of people worldwide, beyond Korea, through innovative new drug development and strengthening ESG management, will continue to illuminate Yuhan Corporation’s path forward. The next 100 years are even more anticipated.

게시물 Yuhan Corporation Accelerates Global Leap with Lazertinib’s European Commercialization이 솜삽 블로그에 처음 등장했습니다.